US Oncology Applauds Journal Of Clini...

US Oncology Applauds Journal Of Clinical Oncology Study Highlighting...

There are 1 comment on the MediLexicon story from May 3, 2008, titled US Oncology Applauds Journal Of Clinical Oncology Study Highlighting.... In it, MediLexicon reports that:

“The NOPR project itself represents a new benchmark for cooperation between CMS and the medical imaging community to help determine the value of new imaging technologies and their impact on patient management”

Main Category: Cancer / Oncology Also Included In: MRI / PET / Ultrasound Article Date: 02 May 2008 US Oncology, which supports one of the nation's largest cancer treatment and research networks representing ... via MediLexicon

Join the discussion below, or Read more at MediLexicon.

Since: Dec 05

Irvington, NJ

#1 May 5, 2008
Possible indications of whether chemotherapy benefits cancer patients (outcome for metabolic responders and non-responders) can be provided by PET imaging, but the big problem is that with PET imaging, the patient is given potentially toxic and ineffective drugs and need to wait some six to eight weeks and then make tumor measurements.

And then give more potentially toxic and ineffective drugs and wait another six to eight weeks and repeat measurements. You still have the patient getting potentially toxic and ineffective treatment and then you still have to wait weeks until you could try Plan B. You may promote the onset of clinically acquired multi-drug resistance.

Cancer drugs are given based on how large populations are likely to respond to a treatment. However, doctors don't treat populations, they treat individual patients. Because of this, doctors give treatments knowing full well that only a certain percentage of patients will receive a benefit from any given medicine.

A chemo-induced gene mutation can happen when the original chemo received does not work. The cancer comes back. When it does this, the cancer comes back more aggressively. The mutagenic effects (changes in form) of chemotherapy on a genetically-unstable tumor, drives the tumor into a state of more aggressive behavior.

Cancers that are a product of these genetic mutations release cells from the usual controls of proliferation and survival, making them so much harder to fight it. Following this mutation, the cancer cells acquire the ability to proliferate without the normal restraints.

As the cancer grows, it may infiltrate and destroy the surrounding tissue, and metastasize by penetrating into blood vessels, lymph nodes, and body cavities. Distant metastasis via the bloodstream may affect virtually any organ (the lungs, bones, liver, adrenals, and even the brain).

It would be highly desirable to know what drugs are effective against your particular cancer cells before these toxic agents are systemically administered into your body. Having a good tumor-drug match not only would improve survival rates, it would be cost-effective, and the high cost of the newer cancer therapies reinforces the necessity of choosing the right therapy the first time around.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

US Oncology Discussions

Title Updated Last By Comments
News Precision highlights role of ChemoFx test, mult... (Jan '11) Jan '11 gdpawel 1
News Cardinal loaded with optimism after spinoff (Nov '10) Nov '10 Don Lewis 4
News Heavy charges weigh on U.S. Oncology first-quar... (May '07) May '07 gdpawel 2
More from around the web